Trimodulin

Phase 3Small molecule

BBiotest

Trimodulin is one of 64 small molecule programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

COVID-19Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Trimodulin

BBiotest

Phase 3

1 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Pneumonia

NCT05722938

Clinical

Trials by Indication[1]

Pneumonia2 trials

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

Terminated·BBiotest·Phase 3·NCT05531149·107 enrolled

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Recruiting·BBiotest·Phase 3·NCT05722938·590 enrolled

COVID-191 trial

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19

Completed·BBiotest·Phase 2·NCT04576728·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Trimodulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trimodulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trimodulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biotest company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBiotest

Trimodulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Pneumonia2 trials

COVID-191 trial

References

Drug Info

Quick Facts

Related News